

Multivariable Association Discovery in Population-scale

Meta-omics Studies

Himel Mallick^{1,2}, Ali Rahnavard³, Lauren J. McIver^{1,2}, Siyuan Ma^{1,2}, Yancong Zhang^{1,2}, Long H. Nguyen^{1,4,5}, Timothy L. Tickle², George Weingart^{1,2}, Boyu Ren^{1,2}, Emma H. Schwager^{1,2}, Suvo Chatterjee⁶, Kelsey N. Thompson¹, Jeremy E. Wilkinson¹, Ayshwarya Subramanian^{1,2}, Yiren Lu¹, Levi Waldron⁷, Joseph N. Paulson⁸, Eric A. Franzosa^{1,2}, Hector Corrada Bravo⁹, Curtis Huttenhower^{1,2*}

¹Biostatistics Department, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

²The Broad Institute, 415 Main Street, Cambridge, MA 02142, USA

³Computational Biology Institute, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC 20052, USA

⁴Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02144, USA

⁵Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02144, USA

⁶Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA

⁷Department of Epidemiology and Biostatistics, CUNY School of Public Health, NY 10027, USA

⁸Department of Biostatistics, Product Development, Genentech, Inc., South San Francisco, CA 94080, USA

⁹Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD 20742, USA

*Correspondence to chuttenh@hsph.harvard.edu

Abstract

It is challenging to associate features such as human health outcomes, diet, environmental conditions, or other metadata to microbial community measurements, due in part to their quantitative properties. Microbiome multi-omics are typically noisy, sparse (zero-inflated), high-dimensional, extremely non-normal, and often in the form of count or compositional measurements. Here we introduce an optimized combination of novel and established

27 methodology to assess multivariable association of microbial community features with complex
28 metadata in population-scale observational studies. Our approach, MaAsLin 2 (Microbiome
29 Multivariable Associations with Linear Models), uses general linear models to accommodate a
30 wide variety of modern epidemiological studies, including cross-sectional and longitudinal
31 designs, as well as a variety of data types (e.g. counts and relative abundances) with or without
32 covariates and repeated measurements. To construct this method, we conducted a large-scale
33 evaluation of a broad range of scenarios under which straightforward identification of meta-omics
34 associations can be challenging. These simulation studies reveal that MaAsLin 2's linear model
35 preserves statistical power in the presence of repeated measures and multiple covariates, while
36 accounting for the nuances of meta-omics features and controlling false discovery. We also
37 applied MaAsLin 2 to a microbial multi-omics dataset from the Integrative Human Microbiome
38 (HMP2) project which, in addition to reproducing established results, revealed a unique,
39 integrated landscape of inflammatory bowel disease (IBD) across multiple time points and omics
40 profiles.

41 **Keywords:** Human Microbiome, Metagenomics, Differential Abundance Analysis, Multivariable
42 Association, Microbiome Epidemiology, Longitudinal Analysis

43 **Introduction**

44 Human-associated microbiota has been convincingly linked to the development and progression
45 of a wide range of complex, chronic conditions including inflammatory bowel diseases (IBD),
46 obesity, diabetes, cancer, and cardiovascular disorders^{1,2}. Due to recent advances in multiple
47 high-throughput functional profiling technologies, research has expanded well beyond bacteria-
48 specific 16S rRNA gene amplicon profiles to multi-omics surveys, i.e. non-bacterial,
49 metagenomic, metatranscriptomic, metabolomic, and metaproteomic measurements assessed
50 simultaneously in the same biological specimens^{3,4}. Additionally, due to diminishing sequencing

51 costs, longitudinal, within-subject study designs are becoming increasingly common, especially
52 when assessing the microbiome in population health^{5,6}. These large, complex data contain
53 abundant information to enable microbe-, gene-, and compound-specific hypothesis generation
54 at scale. However, robust quantitative methods to do so at scale can still be challenging to
55 implement without excessive false positives - one of the main hurdles in accurate translational
56 applications of the microbiome to human health.

57 One of the primary limitations of leveraging such population-wide multi-omics surveys is thus
58 computational, in part due to the complexity and heterogeneity of microbial community data that
59 have made reliable application of statistical methods difficult. In particular, best practices to guard
60 against spurious discoveries in meta-omics datasets remain scarce⁷⁻¹⁴. High-throughput meta-
61 omics datasets have specific characteristics that complicate their analyses: high-dimensionality,
62 count and compositional data structure, sparsity (zero-inflation), over-dispersion, and hierarchical,
63 spatial, and temporal dependence, among others. To combat these challenges, specialized
64 methods implemented in usable, reproducible software are needed to accurately characterize
65 microbial communities within large human population studies, while maintaining both sensitivity
66 and specificity.

67 Early advances in microbiome epidemiology focused on omnibus testing for identifying overall
68 associations between aggregate microbiome structure and host or environmental phenotypes and
69 covariates (e.g. disease status, diet, antibiotics or medication usage, age, etc.). Many of these
70 rely on permutation-based procedures for moderated significance testing¹¹. These methods
71 assess whether overall community patterns of variation are associated with the covariates of
72 interest, but fail to provide feature-level inference to enable follow-up characterization (where a
73 feature can be any profiled omics abundance, e.g. taxa, genes, pathways, chemicals, etc.) To
74 facilitate actionable outcomes, it is important to discern feature-specific associations at the highest
75 possible resolution. This has led to the development of a variety of per-feature (or feature-wise)

76 association testing methods, most of which are based on similar statistical frameworks, differing
77 primarily in (i) the choice of normalization or transformation, (ii) observation model or likelihood,
78 and (iii) the associated statistical inference¹¹. As compared to omnibus testing approaches, per-
79 feature methods (i) identify associations for each individual feature-metadata pair, (ii) facilitate
80 feature-wise covariate adjustment, and (iii) call out specific features (as opposed to complex
81 combinations of features implicated in associations in omnibus testing), leading to increased
82 interpretability for translational and basic biological applications.

83 Despite a rich literature on feature-wise association testing for microbial communities, methods
84 that can accommodate a wide variety of modern epidemiological study designs remain scarce.
85 For instance, many early methods do not explicitly account for the sparsity observed in microbial
86 meta-omics observations, and only a few scale beyond routine univariate (differential abundance)
87 analyses without becoming overly susceptible to false positive or false negative results^{7,11}.
88 Furthermore, most methods for microbiome data do not explicitly adjust for repeated measures
89 and multiple covariates in a unified statistical framework, a lack of which can have a profound
90 (and typically anti-conservative) impact on subsequent epidemiological inference.

91 Here, we address these issues by providing a flexible approach to identify multivariable
92 associations in large, heterogeneous meta-omics datasets. We have implemented this method
93 as MaAsLin 2 (Microbiome Multivariable Associations with Linear Models, with software version
94 2.0 released with this study), a successor to MaAsLin 1^{15,16}. Unlike MaAsLin 1's single-model
95 framework based on applications of arcsine square root-transformed linear model following Total
96 Sum Scaling (TSS) normalization^{15,16}, MaAsLin 2 has evaluated and combined the best set of
97 analysis steps to facilitate high-precision association discovery in microbiome epidemiology
98 studies. It provides a coherent paradigm through a multi-model framework with arbitrary
99 coefficients (phenotypes and covariates) and contrasts of interest, along with support for data
100 exploration, normalization, and transformation options to aid in the selection of appropriate data-


101 and design-driven statistical techniques for analyzing microbial multi-omics data. In this study, we
102 also conducted a large-scale synthetic evaluation of a broad range of circumstances under which
103 straightforward identification of meta-omics features can be challenging. These simulation studies
104 revealed that MaAsLin 2 preserves statistical power in the presence of repeated measurements
105 and multiple covariates while accounting for the nuances of meta-omics features and, critically,
106 controlling false discovery rates. We concluded with an application to novel biomarker discovery
107 in multiple omics datasets from the Integrative Human Microbiome Project (iHMP or HMP2⁶). The
108 implementation of MaAsLin 2, associated documentation and tutorial, and example data sets are
109 freely available in the MaAsLin 2 R/Bioconductor software package at
110 <https://huttenhower.sph.harvard.edu/maaslin2>.

111 **Results**

112 **MaAsLin 2 methodology and validation**

113 MaAsLin 2 provides a comprehensive multi-model system for performing multivariable
114 association testing in microbiome profiles - taxonomic, functional, or metabolomic - with analysis
115 modules for preprocessing, normalization, transformation, and data-driven statistical modeling to
116 tackle the challenges of microbial multi-omics (compositionality, overdispersion, zero-inflation,
117 variable library size, high-dimensionality, etc.; **Fig. 1A**). The MaAsLin 2 implementation requires
118 two inputs: (i) microbial feature abundances (e.g. taxa, genes, transcripts, or metabolites) across
119 samples, in either counts or relative counts; and (ii) environmental, clinical, or epidemiological
120 phenotypes or covariates of interest (together “metadata”). Both metadata and microbial features
121 are first processed for missing values, unknown data values, and outliers. If indicated, microbial
122 measurements are then normalized and transformed to address variable depth of coverage
123 across samples. Feature standardization is optionally performed, and a subset or the full
124 complement of metadata are used to model the resulting quality-controlled microbial features and

125 define p-values for each metadata association per feature using one of a wide range of possible
 126 multivariable models. After all features are evaluated, p-values are adjusted for multiple
 127 hypothesis testing and a table summarizing statistically significant associations is reported. While
 128 the default MaAsLin 2 implementation uses a log-transformed linear model on TSS-normalized
 129 quality-controlled data, the software supports several other statistical models including GLM (e.g.
 130 Negative Binomial¹⁷), zero-adjusted models (e.g. Compound Poisson^{18,19}, ZINB²⁰), and multiple
 131 normalization/transformation schemes under one estimation umbrella. In the presence of
 132 repeated measures, MaAsLin 2 additionally identifies covariate-associated microbial features by
 133 appropriately modeling the within-subject (or environment) correlations in a mixed model
 134 paradigm, while also accounting for inter-individual variability by specifying between-subject
 135 random effects in the model. A variety of summary and diagnostic plots are also provided to
 136 visualize the top results.



137
 138 **Figure 1: MaAsLin 2 for feature-wise association of microbial communities with phenotypes. A)** MaAsLin 2 is a statistical
 139 method for association analysis of microbial community meta-omics profiles. It comprises several steps, including data transformation,
 140 multivariable inference, multiple hypothesis test correction, and visualization. These are based on a set of flexible and computationally
 141 efficient linear models, while accounting for the nuances of microbiome data, repeated measures, and multiple covariates. **B)**
 142 Comprehensive benchmarking of multivariable methods for microbiome epidemiology. To identify appropriate methods for associating
 143 microbiome features with health outcomes and other covariates, we assessed up to 84 combinations of normalization/transformation,
 144 zero-inflation, and regression models (**Supplementary Fig. S1A**). These were applied to synthetic data using a hierarchical model
 145 (SparseDOSSA, <http://huttenhower.sph.harvard.edu/sparsedossa>) to generate realistic, model-agnostic datasets with varying scopes
 146 and effect sizes of microbiome associations. Individual per-feature association methods were performed repeatedly to evaluate

147 method-specific recall and precision measures. **C)** Association method performance summary across major evaluation criteria. Three
148 aspects of performance were considered: (i) false discovery, (ii) sensitivity, and (iii) computational efficiency. Evaluation metrics are
149 shown (in rows) for the resulting microbial multivariable association methods (both state-of-the-art and novel), averaged over all
150 simulation parameters (**Supplementary Fig. S1B**). The top-performing methods (as measured by average F1 score) from each class
151 of models (**Supplementary Fig. S1C**) are shown (in columns). With the exception of Spearman and Wilcoxon that maintained best
152 performance on TSS-normalized data, all methods exhibited superior performance with no/default normalization (ANCOM,
153 metagenomeSeq, metagenomeSeq2, DESeq2, edgeR, MaAsLin 1, MaAsLin 2, limma VOOM, ZIB) or library size normalization in
154 which log-transformed library size is included as an offset in the associated GLM likelihood (Compound Poisson, Negative Binomial,
155 ZINB). Top colored boxes represent method characteristics including the capability to handle zero-inflation and random effects. Based
156 on synthetic evaluations, MaAsLin 2 includes optimized default models for epidemiological testing in microbial multi-omics data.

157 To identify model components appropriate for MaAsLin 2's microbiome feature association testing
158 and to objectively benchmark current association methods, we assessed realistic synthetic
159 datasets generated by SparseDOSSA (full details of individual association methods, as well as
160 simulation parameters, are described in **Methods** and are available online at
161 https://github.com/biobakery/maaslin2_benchmark). Briefly, SparseDOSSA is a synthetic data
162 generation routine that models biologically plausible synthetic data from diverse template
163 microbiome profiles by taking into account (i) feature-feature, (ii) feature-metadata, and (iii)
164 metadata-metadata correlations, superseding previous efforts by including multiple covariates
165 and longitudinal designs (**Methods**). As compared to previous simulation schemes,
166 SparseDOSSA allows multivariable spike-in both in the presence and absence of repeated
167 measures, as well as arbitrary covariance structure in the metadata design matrix.

168 For this study, we carried out several spike-in experiments to induce and test controlled
169 associations, as governed by configurable simulation parameters (**Supplementary Fig. S1**).
170 When used for this purpose, SparseDOSSA first generates null microbial community features
171 containing no significant association patterns using a Bayesian hierarchical model independently
172 of metadata features (**Fig. 1B, Methods**). In addition to varying sample size and feature
173 dimension, a broad range of metadata and experimental designs are then considered, including
174 repeated measures and univariate and multivariate covariates (both continuous and binary) of
175 varying dimension and effect size (**Supplementary Fig. S1A**). Specifically, in each instance, we
176 varied sample sizes from small (10) to large (200) for a fixed feature size (up to 500), and within
177 each sample size, the effect size parameter was again varied from modest (e.g. <2-fold

178 differences) to strong (10-fold). In each simulation, 10% of features (and 20% of metadata for
179 multivariable scenarios) were modified as an in-silico spike-in. Precision and recall measures
180 were averaged over 100 simulation runs (**Supplementary Fig. S1B, Methods**). All methods were
181 corrected for multiple hypothesis testing using standard approaches for FDR control, declaring
182 significant associations at a target of FDR 0.05. For a fair comparison, a basic, model-free filtering
183 step to remove low-abundance features was performed before statistical modeling for all
184 methods. Methods unable to process specific simulation configurations due to high computational
185 overhead or slow convergence were omitted for those cases.

186 To compare the detection power of various methods in identifying true positive feature
187 associations, we first comprehensively evaluated published metagenomic tools and
188 representative methods for bulk RNA-seq analysis within each simulation scenario. These
189 methods were combined with several microbiome-appropriate normalization, transformation, and
190 linkage models (**Supplementary Fig. S1C, Methods**). In particular, we considered six distinct
191 categories of methods in our evaluations: (i) published methods specifically designed for microbial
192 community, such as metagenomeSeq²¹, ANCOM^{14,22}, and ZIB^{23,24}, (ii) published bulk RNA-seq
193 differential expression methods, such as DESeq2²⁵, edgeR²⁶, and limma VROOM^{27,28}; (iii) existing
194 generalized linear model (GLM) count models, such as the negative binomial¹⁷, (iv) methods
195 based on linear models, such as limma²⁹ and “pure” linear models (LMs); (v) representative zero-
196 adjusted methods from the microbiome and scRNA-seq literature such as the compound
197 Poisson^{18,19} and the zero-inflated negative binomial (ZINB^{20,30}); and finally (vi) traditional,
198 simplistic non-parametric methods, such as Spearman correlation and Wilcoxon tests. Of note,
199 many of these methods can only compare two groups (i.e. a single binary metadatum), and not
200 all are compatible with continuous and multivariate metadata, resulting in a distinct set of
201 comparable methods for each experimental design.

202 Our first consideration in designing MaAsLin 2 for microbiome epidemiology was to ensure that
203 both current statistical theory and practical issues were considered during the analysis of
204 microbiome multi-omics data. To this end, we rigorously characterized various finite-sample
205 properties of different association methods focusing on three broadly defined aspects: (i) false
206 discovery, (ii) detection power, and (iii) software implementation, with multiple performance
207 indicators for each category (**Fig. 1C**). Rather than focusing on a single evaluation metric like the
208 Area Under the Curve (AUC) or the False Positive Rate (FPR), we ranked methods based on a
209 combination of metrics (**Methods**), many not considered in previous benchmarking. To
210 summarize each evaluation criteria, a normalized continuous score ranging between 0 and 1 was
211 assigned (**Methods**). Methods were then eliminated based on the presence of 'red flags' with
212 respect to at least one evaluation criteria, i.e. extreme departures from the best possible value.
213 Finally, metrics that are mainly descriptive rather than quantitative were also evaluated (e.g. the
214 ability to handle complex metadata designs, zero-inflation, or repeated measures) to achieve a
215 final consensus. This tiered strategy not only allowed us to select a set of "best" methods based
216 on the fewest 'red flags' across all scenarios, but also to identify a method that is (i) sufficiently
217 robust to false discovery control and detection power, (ii) scalable to large multi-omics datasets,
218 and (iii) accommodating of most modern epidemiological designs and microbial data types.

219 Notably, previous benchmarking in this area has only focused on differential abundance testing
220 without the simultaneous consideration of multiple covariates and repeated measures⁷⁻⁹.
221 Additionally, with the exception of Hawinkel et al.⁷, these benchmarking efforts lacked important
222 considerations to the extent that they either (i) did not consider FDR as a metric of evaluation^{9,31,32}
223 or (ii) misreported false positive rate as FDR⁸ (**Methods**). While a majority of these studies made
224 a final recommendation based on the traditional AUC metric or a combination of sensitivity and
225 specificity, we argue that without considering the FDR-controlling behavior of a method, the AUC
226 values alone are too optimistic to draw any meaningful conclusions about its practical utility. In

227 other words, particularly for biological follow-up, high precision among the most confident (lowest
228 recall) predictions is essential. To this end, our large-scale benchmarking enables a progressive
229 unification of traditional and practically important evaluation metrics by providing a comprehensive
230 connected view of microbiome multivariable association methods, especially in the context of
231 modern study designs, multiple covariates, and repeated measures.

232 Overall, our simulation study revealed that virtually all high-sensitivity methods with an
233 overoptimistic median AUC, especially those targeted to microbial communities, exhibited a highly
234 inflated average FDR (**Fig. 1C**). A similar pattern was observed for other AUC-like measures such
235 as F1 score and Matthew's correlation coefficient (MCC). On the other end of the spectrum,
236 compositionality-corrected methods such as ANCOM exhibited an extreme departure from 'good'
237 performance with respect to several criteria including sensitivity and p-value calibration, as
238 measured by both Conservative and Total Area⁷ (**Methods**). Overall, these simulations reveal
239 that while there is no single method that outperforms others in all scenarios, MaAsLin 2 was the
240 only multivariable method tested that controlled FDR with the fewest 'red flags' across scenarios
241 (**Fig. 1C**).

242 This initial phase of our study thus expands the understanding of statistical association methods
243 appropriate for microbial community data under varying study designs, and it especially highlights
244 the inability of many common methods to control false discoveries. This is of critical importance
245 to past and present microbiome association methods, as failure to control the FDR causes
246 uncertainty in both scientific reproducibility and interpretability. Based on these evaluations, a
247 linear model with TSS normalization and log transformation was adopted as the default model in
248 MaAsLin 2, and the software provides several flexible options to apply a combination of other
249 normalization, transformation, and statistical methods to customize specific analysis tasks. The
250 implementation of MaAsLin 2, associated documentation, and example data sets are freely
251 available in R/Bioconductor and at <https://huttenhower.sph.harvard.edu/maaslin2>.


252 **MaAsLin 2 controls false discovery rate while maintaining power in differential** 253 **abundance analysis**

254 Differential abundance testing for microbial community features (taxa, pathways, etc.) is one of
255 the most commonly used strategies to identify features that differ between sample categories
256 such as cases and controls. Despite a large number of developments in the area, a lack of
257 consensus on the most appropriate statistical method has been a major concern¹¹. To model
258 experimental designs of this type, we used synthetic count data with spiked-in features
259 differentially abundant between two defined groups of samples. In particular, we multiplied the
260 mean relative abundance of a randomly sampled fraction of 10% of the features with a given
261 effect size (fold change) in one of the groups and renormalized the ensemble of relative
262 abundances to a unit sum to create features differentially abundant between groups. We repeated
263 this procedure for each unique combination of sample size (10, 20, 50, 100, 200), feature
264 dimension (100, 200, 500), and fold change (1, 2, 5, and 10), each time summarizing performance
265 over 100 simulation runs (**Methods**). Before model fitting, features with a low prevalence (<10%)
266 were trimmed from the generated data sets.

267 As in our overall evaluation (**Fig. 1C**), we observed marked differences between the FDR-
268 controlling behavior of different methods in the simple case of single binary metadata and non-
269 longitudinal design, in some cases exceeding 75% (**Fig. 2**). Among the methods with good, robust
270 FDR control, only those based on linear models achieved moderate power, whereas, for methods
271 such as DESeq2 and edgeR, the FDR control came at the cost of reduced power. Among other
272 methods, practically all count and zero-inflated models, as well as newer methods based on log-
273 ratios such as ANCOM, struggled to correctly control the FDR at the intended (nominal) level, and
274 the best performance in this class of methods was obtained by metagenomeSeq2, Compound
275 Poisson, and ZINB (as measured by the F1 score). Many of the remaining methods were too
276 liberal, with metagenomeSeq and Negative Binomial standing out with a large number of false

277 positive findings. Overall, linear models (LMs) remained critically the only class of methods tested
278 that has good control of FDR across study designs, and they all exhibited a boost in statistical
279 power with increased sample size and association strength (**Supplementary Fig. S2**).

280 We also evaluated the average FPR of these methods by recording the fraction of tested
281 unassociated (negative) features that were deemed significant following FDR correction. Nearly
282 all methods controlled the FPR well below the imposed level (**Supplementary Fig. S3**). Relatedly,
283 we employed a previously proposed metric called “departure from uniformity” (i.e. departure from
284 uniformity of p-value under the null), which, complementary to FPR, quantifies the liberal or
285 conservative area between observed and theoretical quantiles of a uniform distribution⁷
286 (**Methods**). As expected, methods with high average false discovery rates, including zero-inflated
287 and count models, showed extreme departures from uniformity in the liberal direction, whereas
288 conservative methods such as DESeq2 and edgeR showed the same in the opposite direction,
289 suggesting extreme violation of uniformly distributed p-values under the null hypothesis
290 (**Supplementary Fig. S4**). While these results raise potential concerns about the FDR-controlling
291 behaviors of most existing methods, LM-based approaches did not exhibit this trend. In general,
292 tools based on linear models (such as limma) performed very similarly when calibrated with
293 MaAsLin 2's default model parameters, as expected, but not with their recommended default
294 parameters (**Supplementary Fig. S3**). Additionally, their options for handling sparsity and
295 compositionality were generally not appropriate for microbiome data. Amplicon, metagenomic
296 taxonomic, and functional profiles each show distinct count and zero-inflation properties, for
297 example, that are best handled by a multi-model system. As such, in addition to the binary
298 metadata design, we repeated the above simulation experiments for univariate continuous
299 metadata as well, which led to similar conclusions (**Supplementary Fig. S5**), further supporting
300 MaAsLin 2's default model's performance across metadata types and experimental designs.



301

302 **Figure 2: MaAsLin 2 controls false discovery rate while maintaining power in differential abundance analysis of microbial**
303 **communities.** To assess models' behaviors during differential abundance analysis, we simulated 100 independent datasets per
304 parameter combination, each containing a single binary metadata and a fixed number of true positive features (10% of features
305 differentially abundant) for varying association strengths and sample sizes (**Supplementary Fig. S1C**). We then evaluated the ability
306 of different microbiome association methods to recover these associations using a variety of performance metrics and summarized
307 the results across runs (**Methods**). Both sensitivity and false discovery rates (FDR) are shown for the best-performing method from
308 each class of models (as measured by average F1 score; **Methods**; full results in **Supplementary Figs. S2-S5**). Compared to zero-
309 inflated and count-based approaches, MaAsLin 2's linear model formulation consistently controlled false discovery rate at the intended
310 nominal level while maintaining moderate sensitivity. Red line parallel to the x-axis is the target threshold for FDR in multiple testing.
311 Methods are sorted by increasing order of average F1 score across all simulation parameters in this setting.

312 As a final evaluation, we assessed the impact of various normalization schemes on the associated
313 statistical modeling, evaluating all combinations of normalizations appropriate for each applicable
314 method (**Supplementary Fig. S1C, Methods**). Focusing on the best-performing linear models,
315 we found that model-based normalization schemes such as relative log expression (RLE³³) as
316 well as data-driven normalization methods such as the trimmed mean of *M*-values (TMM³⁴) and
317 cumulative sum scaling (CSS²¹) led to good control of FDR, but they also led to a dramatic
318 reduction in statistical power (**Supplementary Figs. S3, S5**). In contrast, TSS showed the best
319 balance of performance among all tested normalization procedures, leading to more powerful

320 detection of differentially abundant features. These results have potential implications for other
321 analyses in addition to differential abundance testing, as normalization is usually the first critical
322 step before any analysis of microbiome data, and an inappropriate normalization method may
323 severely impact post-analysis inference. In summary, our synthetic evaluation indicates that TSS
324 normalization, although simplistic in nature, may be superior to other normalization schemes
325 especially in the context of feature-wise differential abundance testing (and more generally for
326 multivariable association testing, as described later), in addition to community-level comparisons
327 as previously described³⁵.


328 **MaAsLin 2 facilitates multivariable association discovery in population-scale** 329 **epidemiological studies**

330 Moving beyond univariate comparisons, we next assessed MaAsLin 2's performance in
331 multivariable association testing in comparison to other methods. Although widespread in
332 microarray and gene expression literature, multivariable analysis methods have remained
333 underdeveloped in microbial community studies. From an epidemiological point of view,
334 coefficients from a covariate-adjusted regression model are arguably more interpretable than its
335 individual, unadjusted counterparts. As a result, major conclusions from existing benchmarking
336 studies geared towards univariate associations are not generalizable to this broader setting,
337 where challenges such as zero-inflation and multiple testing are likely to be exacerbated,
338 especially in relation to multiple rounds of independently conducted univariate analyses as
339 commonly practiced.

340 To introduce multivariable associations into synthetically generated microbial feature profiles, we
341 supplemented each "sample" with multiple covariates consisting of both binary and continuous
342 metadata, either independent or correlated (**Supplementary Fig. S1A, Methods**). In each of
343 these datasets, 10% randomly selected features were modified ("spiked") to be associated with

344 randomly chosen 20% metadata features with a given magnitude (effect size). After spiking in,
345 samples were rescaled to their original (simulated) sequencing depth. As before, we repeated this
346 procedure for each unique combination of sample size (10, 20, 50, 100, 200), feature dimension
347 (100, 200, 500), and effect size (1, 2, 5, and 10), each time summarizing performance over 100
348 simulation runs.

349 The results from this set of simulations revealed that MaAsLin 2's default linear model had the
350 highest sensitivity among the methods that controlled the FDR at the target level, which also
351 remained consistent at larger sample sizes and stronger effect sizes (**Fig. 3**). We also observed
352 an improvement in performance when TSS normalization was employed (as compared to no
353 normalization) but did not observe similar improvement for other normalization methods
354 (**Supplementary Fig. S6**). As before, zero-inflated and count models failed to control the FDR at
355 the nominal level, in the sense that the actual FDR was always above the nominal threshold used
356 for identifying significant features - a phenomenon that was surprisingly consistent regardless of
357 the metadata covariance structure (**Supplementary Fig. S7**). Taken together, these findings
358 further confirm that MaAsLin 2's default linear model is able to detect relevant associations across
359 a broad range of metadata designs, facilitating population-level analyses of microbial
360 communities.



361


362 **Figure 3: MaAsLin 2 facilitates multivariable association discovery in large-scale human epidemiological and other microbial**
 363 **community studies.** Synthetic datasets containing five “metadata” with varying types of induced feature associations were analyzed
 364 using a variety of multivariable approaches (**Supplementary Fig. S1C**). As measured by power (recall) and false discovery rate (FDR),
 365 MaAsLin 2’s default linear model outperformed other methods in controlling FDR while maintaining power across true-positive fold-
 366 change values, regardless of the total number of features. As expected, MaAsLin 2 has better power for stronger effect sizes,
 367 eventually attaining the highest power among all FDR-controlling methods. Red line parallel to the x-axis is the nominal FDR. Values
 368 are averages over 100 iterations for each parameter combination. The x-axis (effect size) within each panel represents the linear
 369 effect size parameter; a higher effect size represents a stronger association. For visualization purposes, the best-performing methods
 370 from each class of models (as measured by average F1 score; **Methods**; full results in **Supplementary Figs. S6-S7**) are shown.
 371 Methods are sorted by increasing order of average F1 score across all simulation parameters in this setting.

372 **MaAsLin 2 enables targeted microbiome hypothesis testing in the presence of**
 373 **repeated measures**

374 To further validate MaAsLin 2 for longitudinal (or other repeated measures) microbiome data, we
 375 modified our simulation scheme to introduce subject-specific random effects - a key feature of
 376 modern microbiome population studies³⁶. To this end, we tested MaAsLin 2 and related methods
 377 on two types of study designs. The first comprised univariate binary metadata designed to be
 378 challenging by the inclusion of non-independence of the data across time points. Second, we also
 379 simulated more realistic datasets using multiple independent covariates specific to longitudinal

380 microbiome studies. In both these regimes, realistic data were generated using SparseDOSSA
381 each with five time points²⁴, as in previous studies, but after introducing within-subject correlations
382 and between-subject random effects drawn from a multivariate normal distribution (**Methods**). It
383 is to be noted that the set of evaluable models is greatly reduced from the previous set of cross-
384 sectional association tests, as methods not capable of assessing repeated measures were
385 discarded.

386 Using these longitudinal synthetic “microbial communities,” we compared the estimation and
387 inference from MaAsLin 2 with those of the existing methods, which revealed that MaAsLin 2 had
388 much lower false discovery rates than alternatives including ZIB (**Fig. 4, Supplementary Figs.**
389 **S8-S11**), a method specifically designed for microbiome longitudinal data. Both ZIB and MaAsLin
390 2’s linear mixed-effects models are capable of identifying covariate-associated features by jointly
391 modeling all time points. However, the computational overhead of ZIB is significantly higher than
392 that of MaAsLin 2, which is prominent even for small datasets (**Supplementary Fig. S12**).
393 Notably, although not nearly as severe as count-based and zero-inflated models, MaAsLin 2 had
394 a slightly inflated FDR in the univariate repeated measures scenario (**Fig. 4A**) but not in the
395 multivariable scenario (**Fig. 4B**). Among other methods, GLM-based methods such as Negative
396 Binomial and Compound Poisson performed similarly to their non-longitudinal counterparts for
397 both normalized and non-normalized counts (**Supplementary Figs. S8-S9**). This remained
398 consistent for both univariate continuous metadata (**Supplementary Fig. S10**) as well as multiple,
399 correlated covariates (**Supplementary Fig. S11**). Overall, these results suggest that MaAsLin 2’s
400 linear mixed effect model consistently provides lower false discovery rates across metadata
401 designs and can effectively aid in testing differential abundance and multivariable association of
402 longitudinal microbial communities.



403

404 **Figure 4: MaAsLin 2 enables targeted microbial feature testing in the presence of repeated measures.** Results on simulated
 405 data comprising SparseDOSSA-derived compositions with five repeated measures per sample. The FDR is close to the target 0.05
 406 level for MaAsLin 2's default linear model but not for zero-inflated and count models. As before, MaAsLin 2's linear model is
 407 consistently better powered than both negative binomial and limma VOOm at comparable FDR values, which remains consistent for
 408 both univariate continuous metadata (A) and multivariable mixed metadata designs (B) (a combination of continuous and binary
 409 covariates with five metadata features; **Methods**, full results in **Supplementary Figs. S8-S11**). The red line parallel to the x-axis is
 410 the given threshold for FDR in multiple testing. Within each panel, methods are sorted by increasing order of average F1 score across
 411 all associated simulation parameters in each setting.

412 Multi-omics associations from the Integrative Human Microbiome Project

413 We applied MaAsLin 2 to identify relevant microbial features associated with the inflammatory
 414 bowel diseases (IBD) using longitudinal multi-omics data from the Integrative Human Microbiome
 415 Project (iHMP or HMP2³⁶). The HMP2 Inflammatory Bowel Disease Multi-omics (IBDMDB)
 416 dataset included 132 individuals recruited in five US medical centers with Crohn's disease (CD),
 417 ulcerative colitis (UC), and non-IBD controls, followed longitudinally for one year with up to 24
 418 time points each (**Methods**).

419 Integrated multi-omics profiling of the resulting 1,785 stool samples generated a variety of data
420 types including metagenome-based taxonomic profiles as well as metagenomic and
421 metatranscriptomic functional profiles, producing one of the largest publicly available microbial
422 multi-omics datasets. Metagenomes and metatranscriptomes were functionally profiled using
423 HUMAnN 2³⁷ to quantify MetaCyc pathways³⁸, and taxonomic profiles from metagenomes were
424 determined using MetaPhlAn 2³⁹ (**Methods**). For each of these data modalities (i.e. taxonomic
425 profiles and DNA/RNA pathways), independent filtering was performed before downstream
426 testing to reduce the effect of zero-inflation on the subsequent inference. In particular, features
427 for which the variance across all samples was very low (below half the median of all feature-wise
428 variances) or with >90% zeros were removed³⁶. To further remove the effect of redundancy in
429 pathway abundances (explainable by at most a single taxon), only features (both DNA and RNA)
430 with low correlation with individual microbial abundances (Spearman correlation coefficient <0.5)
431 were retained.

432 We first used the IBDMDB to perform an additional semi-synthetic evaluation of association
433 methods' performance in "real" data, specifically when attempting to associate randomized, null
434 microbial taxonomic profiles to covariates. To this end, we permuted all samples 1,000 times to
435 construct shuffled "negative control" datasets, each time assessing the number of significant
436 associations (unadjusted $p < 0.05$) for each applicable method. These were averaged across
437 iterations to derive the expected number of null associations per method (which should remain
438 near-zero under usual circumstances). In particular, we fit (i) a baseline model as a function of
439 IBD diagnosis (a categorical variable with non-IBD as the reference group) while adjusting for
440 enrollment age (as a continuous covariate) and antibiotic use (as a binary covariate), and (ii) a
441 mixed effects model (with subject as random effects) with IBD dysbiosis state as an additional
442 time-varying covariate in addition to the time-invariant covariates considered in the baseline
443 model. Consistent with prior simulations, we found that several methods produced inflated

444 empirical type I error rates (**Supplementary Fig. S13**). This conclusion remained unchanged
445 across varying significance thresholds, and as a result, we did not further apply these methods to
446 the non-permuted data. Relevantly and importantly, linear models did not suffer from this problem,
447 providing additional support for MaAsLin 2's robustness to false positive findings.

448 To dissect dysbiotic changes in IBD at greater resolution, we applied MaAsLin 2 to each individual
449 microbial feature type (i.e. species and DNA/RNA pathways) to test association with IBD
450 phenotype while controlling for IBD dysbiosis state, diagnosis, age, and antibiotic use (**Fig. 5**;
451 **Methods**). Nominal p-values for UC- and CD-specific effects were subjected to multiple
452 hypothesis testing correction using the Benjamini-Hochberg method⁴⁰ with an FDR threshold of
453 0.25. MaAsLin 2 identified a comparable number of significant associations with those initially
454 reported by the IBDMD³⁶. Among microbial species, MaAsLin 2's default linear model identified
455 206 significant associations, among which 150 (72.8%) overlapped with the original study
456 (**Supplementary Fig. S14**). MaAsLin 2 also reported many significant associations that were not
457 discovered in the original study (**Supplementary Dataset S1**). For instance, we observed a
458 significant increase in *Bacteroides ovatus* in both UC and CD dysbiotic patients that was not
459 previously captured, as well as detecting (with MaAsLin 2's increased power) specific depleted
460 *Roseburia* species (*R. inulinivorans* and *R. hominis*) not captured by the previous analysis.
461 Notably, top hits from both MaAsLin 2 and the original study yielded nearly identical rankings
462 across data types, which broadly manifested as a characteristic increase in facultative anaerobes
463 at the expense of obligate anaerobes, in agreement with the previously observed depletion of
464 butyrate producers such as *Faecalibacterium prausnitzii* in IBD (**Fig. 5A**).

465 As an additional validation, we next re-analyzed the HMP2 taxonomic and functional profiles using
466 a zero-adjusted model (implemented in MaAsLin 2 as the compound Poisson). While this
467 maintained type-I error control in our shuffled data validation (as did the default linear model,
468 **Supplementary Fig. S13**), it was generally less desirable due to FDR inflation in simulations


469 **(Figs. 2-4)**. In terms of the number of differentially abundant features detected, both the default
470 linear model and the compound Poisson model performed similarly, with a significant overlap
471 between the top hits identified by each method (**Supplementary Fig. S15**). Among other
472 methods, ZIB and limma VOOM also maintained good Type I error control in these experiments,
473 although again both underperformed along other axes in our simulation studies. These results
474 further strengthen the finding that a combination of controlled parametric simulations and
475 ‘negative control’ experiments based on data shuffling are useful together in identifying methods
476 for real-world applications, as the lack of either can lead to misleading (and irreproducible)
477 conclusions across independent evaluations⁷. This also highlights the flexibility of MaAsLin 2’s
478 multi-analysis framework, wherein researchers are well-served with multiple (i) normalization
479 schemes, (ii) statistical models, (iii) multiplicity adjustments, (iv) multiple fixed and random effects
480 specifications, and (v) in-built visualization and pre-processing options, facilitating seamless
481 application of methods across diverse experimental designs under a single estimation umbrella.

482 Finally, in addition to taxonomic associations, MaAsLin 2 also detected 492 and 58 significant
483 functional associations for metagenomic (DNA) and metatranscriptomic (RNA) pathways,
484 respectively (**Supplementary Datasets S2-S3**), among which 358 (72.7%) and 39 (67.2%)
485 overlapped with the original study (**Supplementary Fig. S14**). While the original analysis of these
486 data included only community-wide functional profiles, we extended this by considering
487 metagenomic and metatranscriptomic functional profiles at both whole-community and species-
488 stratified levels in order to quantify overall dysbiotic functions while simultaneously assigning them
489 to specific taxonomic contributors. In particular, this considers a per-feature DNA covariate model,
490 in which per-feature normalized transcript abundance is treated as a dependent variable,
491 regressed on per-feature normalized DNA abundances along with other regressors in the model
492 **(Methods)**. Surprisingly, bioinformatics and statistics for metatranscriptomics are not yet
493 standardized, and our results indicate that subtle model variations can produce substantially

494 different results, due to the interactions between two compositions (DNA and RNA relative
495 abundances, **Supplementary Dataset S4**). This novel modeling strategy thus led to the discovery
496 of several novel transcript associations relative to the original study.

497 In a majority of these pathways, functional perturbations were driven by shifts in their
498 characteristic contributing taxa (**Fig. 5B**). For example, the most significant DNA pathways
499 enriched in CD patients were characteristic of facultative anaerobes such as *Escherichia coli*,
500 which are broadly more abundant during inflammation. These included pathways such as
501 synthesis of the enterobactin siderophore, lipid A, and sulfate reduction. A second set of enriched
502 pathways was depleted due to the loss of microbes such as *F. prausnitzii*, a particularly prevalent
503 organism that, when abundant, tended to contribute the majority of all enriched pathways it
504 encodes in this cohort (e.g. synthesis of short-chain fatty acids and various amino acids).

505 With the increased sensitivity of this analysis for species-stratified pathways, the overwhelming
506 majority of significant metagenomic differences were attributable solely to the most differential
507 individual organisms, as expected (**Supplementary Datasets 5-6**). Essentially every pathway
508 reliably detectable in *E. coli* was enriched during CD, UC, or both, and most *F. prausnitzii*
509 pathways depleted, along with many pathways from other gut microbes common in “health”
510 (*Bacteroides vulgatus*, *B. ovatus*, *B. xylanisolvens*, *B. caccae*, *Parabacteroides* spp., *Eubacterium*
511 *rectale*, several *Roseburia* spp., and others). Interestingly, since both more potentially causal
512 “driver” pathways, along with all other “passenger” pathways encoded by an affected microbe,
513 are detected by this more sensitive stratified analysis, it can be in many ways more difficult to
514 interpret than the non-stratified, community-wide, cross-taxon metagenomic responses to broad
515 ecological conditions such as immune activity, gastrointestinal bleeding, or oxygen availability.



516

517 **Figure 5: Multi-omics associations from the Integrative Human Microbiome Project. A)** Top 10 significant associations
 518 (FDR < 0.25) detected by MaAsLin 2's default linear model (significance and coefficients in **Supplementary Datasets S1-S3**). All
 519 detected associations are adjusted for subjects and sites as random effects and for other fixed-effects metadata including the subject's
 520 age, diagnosis status (CD, UC, or non-IBD), disease activity (defined as median Bray-Curtis dissimilarity from a reference set of non-
 521 IBD samples), and antibiotic usage. Representative significant associations with dysbiosis state from each 'omics profile are shown:
 522 species (**B**), metagenomic (DNA) pathways (**C**), and metatranscriptomic (RNA) pathways (**D**). Values are log-transformed relative
 523 abundances with half the minimum relative abundance as pseudo count; full results in **Supplementary Datasets S1-S3**.

524 Conversely, differentially abundant microbe- and pathway-specific transcript levels highlighted a
 525 much more specific and dramatic shift toward oxidative metabolism, away from anaerobic
 526 fermentation, and towards Gram-negative (often *E. coli*) growth during inflammation (**Fig. 5C**)⁴¹.

527 Many of these processes were either more extreme during (e.g. gluconeogenesis) or unique to

528 (e.g. glutathione utilization) active CD, as compared to UC. CD and UC responses were opposed
529 in a small minority of cases (e.g. glutaryl-CoA degradation). When stratified among contributing
530 taxa, these differences were almost universally attributable to a few key species, particularly an
531 increase in *E. coli* activity during inflammation and decreases of *F. prausnitzii* transcript
532 representation. Condition-specific transcriptional changes were occasionally contributed (or not)
533 by “passenger” *Bacteroides* spp. (*B. fragilis*, *B. xylanisolvens*, *B. dorei*) instead. Note that these
534 differences include pathways more likely to be “causal” in some sense, as significant
535 transcriptional changes were generally a subset of those detected due to whole-taxon shifts in
536 DNA content (including housekeeping pathways such as general amino acid or nucleotide
537 biosynthesis). These findings further support the importance of disease-specific transcriptional
538 microbial signatures in the inflamed gut relative to metagenomic profiles of functional potential,
539 suggesting that a potential loss of species exhibiting altered expression profiles in disease may
540 have more far-reaching consequences than suggested by their genomic abundances alone.

541 **Discussion**

542 A longstanding goal of microbial community studies, be they for human epidemiology or
543 environmental microbiomes, is to identify microbial features associated with phenotypes,
544 exposures, health outcomes, and other important covariates in large, complex experimental
545 designs. This parallels other methods for high-throughput molecular biology, but microbial
546 community multi-omics must account for properties such as variable sequencing depth, zero-
547 inflation, overdispersion, mean-variance dependency, measurement error, and the importance of
548 repeated measures and multiple covariates. To this end, we have developed and validated a
549 highly flexible, integrated framework utilizing an optimized combination of novel and well-
550 established methodology, MaAsLin 2. This accommodates a wide variety of modern study
551 designs ranging from within-subject, longitudinal to between-subject, cross-sectional, diverse

552 covariates, and a range of quality control and statistical analysis modules to identify statistically
553 significant as well as biologically relevant associations in a reproducible framework. The
554 embedding of these strategies in the paradigm of generalized linear and mixed models enables
555 the treatment of both simple and quite complex designs in a unified setting, improving the power
556 of microbial association testing while controlling false discoveries. To validate this framework, we
557 have extensively evaluated its performance alongside a set of plausible methods for differential
558 abundance analysis in a wide range of scenarios spanning simple univariate to complex
559 multivariable with varying scopes and effect sizes of microbiome associations. Finally, we applied
560 MaAsLin 2 to identify disease-associated features by leveraging the HMP2's multi-omics profile
561 of the IBD microbiome, confirming known associations and suggesting novel ones for future
562 validation.

563 A unique aspect of our synthetic evaluation of microbial community feature-wise association
564 methods while developing MaAsLin 2 is their comprehensive assessment in the presence of
565 multiple covariates and repeated measures, an increasingly common characteristic of modern
566 study designs. To identify covariate-associated microbial features from longitudinal, non-
567 independent measurements, it is necessary to jointly model data from all time points and
568 appropriately account for the within-subject correlations while allowing for multiple covariates.
569 This is particularly critical in the human microbiome, where baseline between-subject differences
570 can be far greater than those within-subjects over time, or of the effects of phenotypes of interest.
571 To the best of our knowledge, the synthetic evaluation presented here is the first to consider such
572 aspects of large-scale microbiome epidemiology in statistical benchmarking. This enabled us to
573 investigate key aspects of published methods that would be difficult to generalize from univariate
574 comparisons alone⁷⁻⁹. Note that the resulting conclusion is largely independent of the association
575 models being evaluated, as the synthetic data were generated from an additional, completely
576 external model (i.e. the zero-inflated log-normal, **Methods**), which is fundamentally different from

577 any of the evaluated parametric methods. Our simulation results thus complement the findings of
578 previous studies in several important aspects. Consistent with previous reports, nearly all zero-
579 inflated models suffer from poor performance (i.e. inflated false positives and higher computation
580 costs), here in both univariate and multivariable scenarios with or without repeated measures.
581 This calls for methodological advancements in statistical modeling of zero-inflated data, as
582 existing theory seems to differ very surprisingly from practice when implemented by established
583 optimization algorithms and applied to noisy data.

584 One noteworthy finding of our evaluation is that a random effect implementation of the same
585 underlying statistical model can lead to different substantive conclusions than its fixed-effects
586 counterpart. This was particularly evident for the negative binomial case, where a substantially
587 better control of FDR (albeit inflated) was observed for the random effect analog. Interestingly,
588 the negative binomial model (with or without zero inflation) is in many ways considered the most
589 “appropriate” model for count-based microbial community profiles, but we observed extremely
590 inconsistent behavior for negative binomial and ZINB implementations during our evaluation, as
591 also observed in previous findings⁴². In particular, our negative binomial evaluation used the
592 *glm.nb()* function from the *MASS* R package⁴³ for fixed-effects and the *glmer()* function from the
593 R package *lme4*⁴⁴ for random effects, whereas the ZINB evaluation used the *zeroinfl()* function
594 from the R package *pscI*⁴⁵. This additionally highlights the potential reproducibility concerns
595 induced by differences in algorithms, implementations, and computational environments even for
596 the same underlying model, suggesting that great caution should be taken when interpreting
597 multiple implementations of the same statistical model for challenging microbial community
598 settings in the absence of an experimentally validated gold standard.

599 In agreement with previous studies, we confirmed that most RNA-seq differential expression
600 analysis tools tend to provide suboptimal performance when applied unmodified to zero-inflated
601 microbial community profiles. In particular, count-based models, due to their strong parametric

602 assumptions on the distributions or parametric specifications of the mean-variance dependency,
603 tend to have inflated FDR when the assumptions are violated. In sharp contrast to previous claims,
604 however, compositionality-corrected methods such as ANCOM^{14,22} as well as specialized
605 normalization and transformation methods such as CLR⁴⁶ did not improve performance over non-
606 compositional approaches^{8,47}, consistent with recent findings that compositional methods may not
607 always outperform non-compositional methods³². Importantly, these conclusions hold regardless
608 of the nature of the modeling paradigm (i.e. univariate vs. multivariable), thus providing a
609 generalizable benchmark for future evaluation studies of applied microbiome association
610 methods. Though we primarily focused on data generated in microbial community surveys, many
611 of our conclusions are extendible to similar zero-inflated count data arising in other applications
612 such as single-cell RNA-seq. Taken together, these simulation results revealed that further
613 investigation into the causes of the failure of FDR correction and development of specialized false
614 positive-controlling methods are important upcoming challenges in microbiome statistical
615 research.

616 Limitations of the current MaAsLin 2 method include, first, its restriction to associating one feature
617 at a time. While this strategy has the advantage of being straightforward to interpret, implement,
618 and parallelize, it sacrifices inferential accuracy by ignoring any correlation structure among
619 features. This can certainly exist due both to compositionality and to biology and will differ e.g.
620 between taxonomic features (related by phylogeny) vs. functional ones (such as pathways). A
621 potential extension would be to adopt an additional multivariate framework that allows modeling
622 simultaneously rather than sequentially, thus improving power by borrowing strength across non-
623 independent features. Second, as revealed by our synthetic evaluation, not surprisingly, linear
624 models remain underpowered in detecting weak effects among microbial communities, especially
625 when accompanied by a small sample size. This is in some ways a necessary consequence of
626 the restrictions of current microbiome measurement technologies, and it emphasizes the

627 importance of an informed power analysis before study planning to ensure an optimal sample size
628 with adequate detection power. Finally, and relatedly, it is not straightforward to incorporate any
629 type of graph structure knowledge such as phylogeny or pathway-based functional roles into the
630 per-feature linear model framework. Bayesian linear models can potentially improve on this by
631 including such information through a suitable prior distribution.

632 Several aspects of microbiome epidemiology remain to be investigated both biologically and
633 computationally, in addition to the challenges addressed here. For example, while it is possible to
634 obtain strain-level resolution from metagenomic sequencing data, strain variants are generally
635 unique to particular individuals rather than broadly carried by many people, presenting unique
636 challenges for strain-level multi-omics. From a computational point of view, this calls for further
637 refinements to MaAsLin 2's methodology when applied to strain-resolved community profiles. In
638 addition, the modeling framework adopted here can only inform undirected associations, and
639 hence cannot be used to infer causation. Advanced methods from other molecular epidemiology
640 fields such as causal modeling and mediation analysis methods can help overcome these
641 issues⁴⁸. Another opportunity for future extension of our method is the integration of established
642 missing data imputation methods across features and metadata, a common pitfall in many
643 molecular epidemiology studies³⁶. Combined, such extensions will lead to further improvement in
644 downstream inference, allowing researchers to investigate a range of hypotheses related to
645 differential abundance and multivariable association.

646 As currently implemented, MaAsLin 2 is designed to be applicable to most human and
647 environmental microbiome study designs, including cross-sectional and longitudinal. Clearly,
648 these can also be extended to additional designs, such as nested case-control and case-cohorts.
649 It is to be noted that MaAsLin 2's capability extends well beyond association analysis. For
650 instance, MaAsLin 2's multi-analysis framework has been used in the context of meta-analysis⁴⁹,
651 and the extracted residuals and random effects from a MaAsLin 2 fit can be used for further

652 downstream analysis (e.g. as has been done in the original HMP2 study for cross-measurement
653 correlation analysis³⁶). By adhering to a flexible mixed effects framework, MaAsLin 2 is able to
654 analyze multiple groups and time points jointly with other associated covariates, which allows
655 formulation of both fixed effects (for cross-sectional associations) and random effects (for within-
656 subject correlations) in a single unified framework. This is particularly appropriate for non-
657 longitudinal studies (those with a small number of repeated measures e.g. multiple tissues or
658 families), or from sparse and irregular longitudinal data from many subjects (e.g. with unequal
659 number of repeated measurements per subject, as commonly encountered in population-scale
660 epidemiology). This aspect could also be extended in the future, based on the increasing
661 availability of dense time-series profiles appropriate for non-linear trajectory-based methods from
662 Bayesian nonparametrics, such as Gaussian processes, particularly in the presence of multiple
663 covariates^{5,50}. Finally, methods need to be developed to accommodate the increasing availability
664 of microbiome-host interactomics and electronic health records in population-scale microbiome-
665 wide epidemiology⁶, moving beyond observational discovery toward translational applications of
666 the human microbiome. In summary, the methodology presented here provides a starting point
667 for more efficient identification of microbial associations from large microbial community studies,
668 offering practitioners a wide set of analysis strategies with state-of-the-art inferential power for the
669 human microbiome and other complex microbial environments.

670 **Methods**

671 **Data for differential feature model evaluations**

672 Synthetic null community abundances

673 Realistic null community data were generated using the SparseDOSSA⁵¹ (Sparse Data
674 Observations for the Simulation of Synthetic Abundances) hierarchical model

675 (<http://huttenhower.sph.harvard.edu/sparsedossa>). SparseDOSSA is a newly developed
676 simulator designed to model the fundamental characteristics of real microbial communities (e.g.
677 zero-inflation, compositionality, etc.) and to simulate new, realistic metagenomic count data with
678 known feature-feature and feature-metadata correlations and provide a gold standard to enable
679 benchmarking of statistical metagenomics methods, superseding previous efforts by including
680 multiple covariates and longitudinal designs.

681 Briefly, SparseDOSSA's Bayesian model captures microbial features (taxon, gene, or pathway
682 abundances) as truncated, zero-inflated log-normal distributions, the parameters of which are
683 hierarchically derived from a parent log-normal distribution. SparseDOSSA estimates feature-
684 specific parameters by fitting to a real-world template dataset, and generates synthetic features
685 from zero-inflated, truncated log-normal distributions based on both fitted and user-defined
686 parameters on a per feature basis (**Supplementary Fig. S1A**). All feature-specific parameters,
687 namely the log-mean, zero-inflation proportion, truncation point, and log-variance are empirically
688 determined to resemble the template dataset's properties. After sampling, the samples are
689 rounded to the nearest integer to mimic count data. A combined dataset of the RISK⁵², PRISM¹⁵,
690 pouchitis¹⁶, and NLIBD⁵³ gut microbiomes, totaling several thousand samples, was used as
691 empirical microbiome template data for the simulations reported in this study. To mimic realistic
692 variation in library size, sequencing depth was generated from a lognormal distribution with
693 average sequencing depth 50,000, resulting in approximately 30-fold to 100-fold variation in
694 sequencing depth.

695 Synthetic metadata generation

696 Simulated metadata matrices in simple univariate cases (UVA, UVB) were generated with
697 continuous values from a standard normal distribution. For the univariate binary case (UVB), we
698 additionally dichotomized the continuous variable by coding samples in the bottom and top half
699 of the distribution as 0 and 1, respectively. For multivariate cases (MVA, MVB), we repeated the

700 above discretization for multiple metadata by first generating from a multivariate normal
701 distribution, and concurrently binarizing half of the metadata features at random. We considered
702 two frequently encountered correlation structures for the multivariate cases: independent and AR
703 (1) with coefficient 0.5, which correspond to MVA and MVB, respectively. Additionally, we
704 considered repeated measures by incorporating random effects in these cross-sectional design
705 matrices. To that end, we generated a simple blocking variable that is normally distributed (with
706 mean 0 and variance 1) across subjects but invariant within subjects, representing a single
707 random effect factor such as subject or time point (block size determined by the simulation
708 parameters as reported in **Supplementary Fig. S1A**). Subsequently, we added this as an
709 additional covariate to the fixed-effects metadata to impose correlations within the blocks,
710 mimicking longitudinal studies. For multivariable cases (MVA, MVB), the number of covariates is
711 fixed to 5. Similarly, for the repeated measures settings, $T = 5$ time points per subject is
712 considered.

713 Multivariable spike-ins of synthetic feature-metadata associations

714 To introduce associations between features and metadata, we used SparseDOSSA's default
715 additive spike-in procedure. Following Weiss et al.⁸, we implement the spike-ins in a balanced
716 way across all metadata to avoid compositional bias. Briefly, SparseDOSSA standardizes both
717 (microbial) features and metadata and randomly chooses (microbial) null features and metadata
718 without replacement. The standardization procedure ensures that the spiked-in features are not
719 dominated by the values of the target metadata but rather distributed similarly to the real data.
720 Next, the standardized non-zero abundances of the selected features are modified by adding a
721 linear combination of all spiked-in standardized metadata, in which a real-valued effect size
722 parameter (**Supplementary Fig. S1A**) governs the strength of association for each associated
723 feature-metadata pair. To create differentially abundant features, a randomly sampled fraction of
724 10% of the features are spiked-in to be associated with the metadata. In the multivariable case,

725 20% of the metadata are randomly selected to be associated with the 10% ‘differentially abundant’
726 features.

727 **Multivariable association test evaluation**

728 Preprocessing, normalizations, and transformations

729 We considered several commonly used normalization procedures including Total Sum Scaling
730 (TSS), Trimmed Mean of *M*-values (TMM³⁴), Relative Log Expression (RLE³³), and Cumulative
731 Sum Scaling (CSS²¹) (**Supplementary Fig. S1C**). For TSS normalization, raw counts were
732 converted into relative abundances by scaling each sample by the total sum (across features).
733 For the remainder, we used the default settings of the edgeR²⁶, DESeq2²⁵, and metagenomeSeq²¹
734 R packages, respectively.

735 In addition to the above normalization procedures, several parametric transformations were also
736 considered. When appropriate, these variance-stabilizing transformations aim at improving
737 parametric estimation models in the presence of violated data assumptions (such as normality
738 and homoscedasticity). These include logit and arcsine square root (AST) for TSS-normalized or
739 proportional relative abundance data, and log transformation (**Supplementary Fig. S1C**). For
740 both log and logit transformations, undefined values were replaced with zeroes (equivalent to
741 adding a small pseudo count of 1 to the zero observations before applying the log transformation).
742 Among other normalization/transformation methods, a ‘Default/None’ category was also
743 considered which represents either (i) default normalization/transformation employed by the
744 associated software or (ii) no normalization/transformation, or (iii) library size normalization in the
745 form of a GLM offset modeling. Prior to applying any normalization and transformation, a basic
746 filtering was performed to prune features absent in >90% of samples. As in previous
747 benchmarking^{7,8,10}, correction for multiple testing was performed using the Benjamini-Hochberg⁴⁰
748 FDR threshold of 0.05.

749 Statistical methods

750 We selected several commonly used methods for differential abundance and multivariable
751 association testing along with a set of experimental methods to apply on the synthetic datasets,
752 using a combination of statistical model and normalization/transformation schemes for each
753 method as appropriate (**Supplementary Fig. S1C**). All tests were conducted using the statistical
754 software R and parallelized using custom bash scripts in a high-performance computing
755 environment (full source code available at: https://github.com/biobakery/maaslin2_benchmark).

756 The selected statistical models (abbreviations in parentheses) are as follows:

- 757 • ANCOM: following Weiss et al.⁸, we used the default implementation of ANCOM¹⁴ using
758 the *ANCOM()* function call with default settings. Unlike other methods, ANCOM does not
759 report p-values but instead returns logical indicators of whether a feature is differentially
760 abundant based on a test statistic *W*. It is to be noted that in the presence of multiple
761 covariates, ANCOM does not return statistically significant feature-metadata pairs with
762 respect to every covariate in the model, making it infeasible for our multivariable setting.
763 Also, we did not test the ANCOM method in repeated measures settings as it was too slow
764 and unstable for assessment, as noted elsewhere³².
- 765 • metagenomeSeq: for the fixed effects, counts were first CSS-normalized with the default
766 quantile supplied by the *cumNormStat()* function and the (log-transformed) CSS-
767 normalized counts were subjected to final testing using *fitZig()*²¹. For random effects,
768 *useMixedModel* was set to TRUE in the *fitZig()* function call.
- 769 • metagenomeSeq2: same as metagenomeSeq²¹, except that the final testing was done
770 using the *fitFeatureModel()* function.
- 771 • DESeq2: for fixed effects, following Thorsen et al.⁹, geometric means were first calculated
772 manually from the raw counts and supplied to the *estimateSizeFactors()* function before

773 calling the *DESeq()* function for final testing²⁵. Random effects modeling compatible with
774 our setting is currently not supported by the DESeq2 software⁵⁴.

775 • edgeR: for fixed effects, following Thorsen et al.⁹, normalization factors were calculated
776 with TMM, which was followed by common and tagwise dispersion estimation steps,
777 before invoking the standard test with the *exactTest()* function²⁶. Random effects modeling
778 compatible with our setting is currently not supported by the edgeR software⁵⁴.

779 • limma: the default functionality of *lmFit()* was applied to the feature counts²⁹. Repeated
780 measures were handled using the *duplicateCorrelation()* function before calling *lmFit()*, in
781 combination with appropriate normalization/transformation (**Supplementary Fig. S1C**).

782 • limma VOOM: same as limma, except that features were subjected to a voom
783 transformation before applying limma^{27,28}.

784 • limma2: same as limma, except that library size or scale factor is included as an additional
785 covariate, in combination with appropriate normalization/transformation (**Supplementary**
786 **Fig. S1C**).

787 • Wilcoxon: the built-in R function *wilcox.test()* using default parameters was applied to the
788 features in combination with appropriate normalization/transformation (**Supplementary**
789 **Fig. S1C**).

790 • Spearman: the built-in R function *cor.test()* was applied to the features in combination with
791 appropriate normalization/transformation (**Supplementary Fig. S1C**).

792 • Linear model (LM): the built-in R function *lm()* with default settings was used in
793 combination with appropriate normalization/transformation (**Supplementary Fig. S1C**).

794 • Linear model (LM2): same as LM, except that library size or scale factor is included as an
795 additional covariate in the model, in combination with appropriate
796 normalization/transformation (**Supplementary Fig. S1C**).

- 797 • Negative binomial (negbin): we used the *glm.nb()* function from the *MASS* package⁴³ and
798 the *glmer.nb()* function from the *lme4* package⁴⁴ for fixed and random effects respectively.
799 In both cases, we used the logarithm of library size (for no normalization) or scaling factor
800 (for other normalization schemes such as CSS, RLE, and TMM) as offset.
- 801 • Zero-inflated Negative Binomial (ZINB): for fixed effects, we used the *zeroinfl()* function
802 from the *pscl* package⁴⁵ with the logarithm of library size (for no normalization) or scaling
803 factor (for other normalization schemes such as CSS, RLE, and TMM) as offset. In the
804 absence of a robust random effect implementation of the same, the ZINB method was not
805 considered in the repeated measures settings.
- 806 • Zero-inflated Beta (ZIB): following Peng et al.²³, we used the *gamlss()* function from the R
807 package *gamlss*⁵⁵ for fixed effects and the *ZIBR()* function from the *ZIBR* R package for
808 random effects²⁴. In both cases, the features are TSS-normalized before statistical testing.
- 809 • Compound Poisson (CPLM): we used the *cpglm()* function from the *cpkm* package⁵⁶ and
810 the *glmmPQL()* function from the *MASS* package⁵⁶ for fixed and random effects
811 respectively. In both cases, we used the logarithm of library size (for no normalization) or
812 scaling factor (for other normalization schemes such as CSS, RLE, and TMM) as offset.
813 No offset was used when combined with the TSS-normalized relative counts.
- 814 • MaAsLin 1: we used the default TSS-normalized, arcsine square root-transformed linear
815 model without gradient boosting^{15,16}.
- 816 • MaAsLin 2: we used the default TSS-normalized, log-transformed linear model with half
817 the minimum relative abundance as pseudo count.

818 Naming convention

819 The nomenclature for the model/normalization/transformation combinations for each method is
820 described in the following set of rules:

- 821 1. For published methods with default parameters, there is no additional identifier following
822 the name of the method, indicating default or no normalization/transformation. These
823 include ANCOM, metagenomeSeq, metagenomeSeq2, limma, limma2, limma VOOM,
824 DESeq2, edgeR, and ZIB.
- 825 2. Similarly, for experimental methods with custom normalization/transformation schemes,
826 no additional identifier simply indicates either no normalization (for non-GLM methods
827 such as LM) or library size normalization (for specific GLMs such as Negative Binomial,
828 Compound Poisson, and ZINB).
- 829 3. Finally, for methods with additional identifiers, method name is always accompanied by a
830 normalization scheme (after the first dot) which is followed by a transformation (after the
831 second dot) except in cases where either no normalization or no transformation is applied.
832 As an example, limma.CSS.LOG denotes a default limma model followed by CSS
833 normalization and log transformation. Similarly, LM.CLR denotes a vanilla linear model
834 followed by a CLR transformation and no normalization, whereas, ZINB.TMM denotes a
835 zero-inflated negative binomial model with TMM normalization and no transformation, and
836 so on and so forth.

837 Performance evaluation

838 Several performance metrics were considered for evaluation, all derived from some combination
839 of the elements from the confusion matrix: false positives (FPs), true positives (TPs), true
840 negatives (TNs), and false negatives (FNs). These include measures related to (i) statistical
841 power, (ii) false discovery, and (iii) software implementation and scope, all as averages over 100
842 simulation runs (**Supplementary Fig. S1B**). Several measures were considered for statistical
843 power - Sensitivity, Area Under the Curve (AUC), and scaled partial AUC (spAUC). The AUC was
844 calculated as the area under the ROC curve, obtained by plotting the sensitivity versus 1-
845 specificity for the varying p-value threshold. spAUC was calculated as the partial area over the

846 high specificity range (0, 0.20), rescaled to mimic the interpretation of AUC (i.e. 0.5 for a random
847 guess and 1 for a perfect classifier using p-values to discriminate between spiked and non-spiked
848 features). The R package *ROCR*⁵⁷ was used to calculate both these AUC measures. We also
849 considered Matthew's correlation coefficient as well as F1 scores as alternate accuracy measures
850 of performance.

851 Among false discovery metrics, maximum and average of several commonly used metrics
852 including False Discovery Rate (FDR) and False Positive Rate (FPR) were considered. When no
853 features were declared significant (i.e. TP = FP = 0), the false discovery rate (FDR) was set to 0.
854 Notably, Weiss et al.⁸ misreported false positive rate as FDR, as evident from the supplemental
855 R code of that paper (Additional files 9 and 10 of Weiss et al⁸). In order to avoid any ambiguity,
856 we provide the analytical expressions of the above-mentioned measures (except AUC and
857 spAUC) as follows:

$$858 \quad \text{FDR (1 - Precision)} = \frac{\text{FP}}{\text{FP} + \text{TP}}$$

$$859 \quad \text{FPR (1 - Specificity)} = \frac{\text{FP}}{\text{FP} + \text{TN}}$$

$$860 \quad \text{Sensitivity (Power or Recall)} = \frac{\text{TP}}{\text{TP} + \text{FN}}$$

$$861 \quad \text{F1 score} = \frac{2\text{TP}}{2\text{TP} + \text{FP} + \text{FN}}$$

$$862 \quad \text{Matthew's correlation coefficient (MCC)} = \frac{\text{TP} * \text{TN} - \text{FP} * \text{FN}}{\sqrt{(\text{TP} + \text{FP}) * (\text{TP} + \text{FN}) * (\text{TN} + \text{FP}) * (\text{TN} + \text{FN})}}$$

863 Following Hawinkel et al.⁷, an alternative measure based on the p-value distribution under the
864 null, 'Departure from Uniformity', was also considered. Briefly, to quantify the departures from
865 uniformity into liberal (or conservative) direction, twice the mean distance between the diagonal
866 line and the points in the QQ plot below (or above) the diagonal was computed. We called these

867 measures 'Liberal Area' and 'Conservative Area', respectively. Both calculated areas are
868 averages over all features, and they both range from 0 to 1. A combined metric called 'Total Area'
869 that defines departure in either direction (defined as Total Area = Liberal Area + Conservative
870 Area) was also computed.

871 Finally, we calculated computational time and convergence aspects of different methods based
872 on their available implementation. Following Soneson and Robinson⁵⁸, we record the actual time
873 required to run each method using a single core and normalize all times for a given data set
874 instance so that the maximal value across all methods is 1 (as reported in **Fig. 1C**). Thus, a
875 'relative' computational time of 1 for a given method and a given data set instance means that this
876 method was the slowest one for that particular instance, and a value of, for example, 0.1 means
877 that the time requirement was 10% of that for the slowest method. Similarly, we estimated the
878 'relative' convergence failure rates for each method, as before, with the worst method as a
879 reference.

880 **Analysis of the iHMP (HMP2) IBDMDB multi-omics dataset**

881 Study design, data, and quality control

882 Data were obtained from the Integrative Human Microbiome Project (HMP2 or iHMP), which is
883 described in detail in Lloyd-Price et al.³⁶ and available through the Inflammatory Bowel Disease
884 Multi-omics Database (IBDMDB, <http://ibdmdb.org>). Briefly, subjects included in this cohort were
885 recruited from five academic medical centers across the US: three pediatric sub-cohorts including
886 Cincinnati Children's Hospital, Massachusetts General Hospital (MGH) Pediatrics, and Emory
887 University Hospital, and two adult sub-cohorts including MGH and Cedars-Sinai Medical Center.
888 132 subjects were followed for one year each to generate integrated longitudinal molecular
889 profiles of host and microbial activity during disease (up to 24 time points each; in total 2,965

890 stool, biopsy, and blood specimens). Self-collected stool samples were transported in ethanol
891 fixative before storage at -80 C until DNA extraction.

892 Multiple measurement types were generated from many individual stool specimens, including 305
893 samples that contain all stool-derived measurements and 791 metagenome-metatranscriptome
894 pairs. Metagenomic data generation and processing were performed at the Broad Institute. After
895 standard sequence- and sample-level quality control as described in Lloyd-Price et al.³⁶, species-
896 level taxonomic abundances were inferred for all samples using MetaPhlAn 2³⁹ and functional
897 profiling was performed by using HUMAnN 2³⁷. The resulting data types including metagenome-
898 based taxonomic abundances and pathway abundance profiles for both metagenomics and
899 metatranscriptomics (summarized as structured pathways from MetaCyc⁵⁹) were used as inputs
900 for MaAsLin 2 analysis.

901 Significance testing with shuffled data

902 In order to quantify whether MaAsLin 2 and other multivariable association methods identified
903 more significant associations than expected by chance (i.e. when all the shared signal between
904 features and metadata are broken), we repeatedly shuffled the metadata sample labels, applied
905 multivariable association methods on the randomized data to link features to metadata, and
906 compared the number of statistically significant associations obtained with these randomized data
907 to the number of statistically significant associations obtained with the original data based on the
908 unadjusted p-values. For a comprehensive comparison of both count and noncount models in this
909 experiment, prior to data shuffling, we multiplied the species-level taxonomic abundances by 5%
910 of the filtered read counts as a “proxy” for the underlying raw sequencing count data. The
911 procedure was repeated 1,000 times to estimate the null distribution of the detection performance
912 in both baseline and longitudinal models (with the exception of Compound Poisson mixed effects
913 model which was repeated 100 times to save computation time). While the baseline model
914 included all time-invariant covariates (age, antibiotic use, IBD diagnosis), the longitudinal model

915 also included subjects as random effects with an additional time-variant fixed effect i.e. IBD
916 dysbiosis state, as stated below.

917 Statistical analysis of species, DNA pathways, and RNA pathways

918 For both species and DNA pathways (whole-community and species-stratified), we regressed the
919 log-transformed relative abundances (with half the minimum relative abundance as pseudo count,
920 the default in MaAsLin 2) using the following per-feature linear mixed-effects model:

$$921 \quad \textit{feature} \sim (\textit{intercept}) + \textit{diagnosis} + \textit{diagnosis/dysbiosis} + \textit{antibiotic use} + \textit{consent age} + (1 | \\ 922 \quad \textit{recruitment site}) + (1 | \textit{subject}).$$

923 Additionally, we modeled the log-transformed relative abundances of the whole-community and
924 species-stratified RNA pathways (with half the minimum relative abundance per feature as
925 pseudo count) using the similar linear mixed-effects model as before, while additionally adjusting
926 the corresponding DNA pathways abundance as a continuous covariate to filter out the influence
927 from gene copies:

$$928 \quad \textit{RNA feature} \sim (\textit{intercept}) + \textit{diagnosis} + \textit{diagnosis/dysbiosis} + \textit{antibiotic use} + \textit{consent age} + \\ 929 \quad \textit{DNA feature} + (1 | \textit{recruitment site}) + (1 | \textit{subject})$$

930 That is, in each per-feature multivariable model, recruitment sites and subjects were included as
931 random effects to account for the correlations in the repeated measures (denoted by (1 |
932 recruitment site) and (1 | subject) respectively) and the transformed abundances of each feature
933 was modeled as a function of diagnosis (a categorical variable with non-IBD as the reference
934 group) and dysbiosis state as a nested binary variable (with non-dysbiotic as reference) within
935 each IBD phenotype (UC, CD, and non-IBD), while adjusting for consent age as a continuous
936 covariate, and antibiotics as a binary covariate. Nominal p-values were adjusted for multiple
937 hypothesis testing with a target false discovery rate of 0.25 with this FDR chosen to match the
938 original study.

939 **Data Availability**

940 The iHMP dataset is publicly available at the IBDMDB website (<https://ibdmdb.org>) and the HMP
941 DACC web portal (<https://www.hmpdacc.org/ihmp/>). The processed HMP2 datasets analyzed in
942 this manuscript are also available as **Supplementary Datasets S1-S6**.

943 **Implementation and Software Availability**

944
945
946 The implementation of MaAsLin 2 is publicly available with source code, documentation, tutorial
947 data, and as an R/Bioconductor package at <http://huttenhower.sph.harvard.edu/maaslin2>. The
948 software packages used in this work are free and open source, including bioBakery⁶⁰ methods
949 available via <http://huttenhower.sph.harvard.edu/biobakery> as source code, cloud-compatible
950 images, and installable packages. Analysis scripts using these packages to generate figures and
951 results from this manuscript (and associated usage notes) are available from
952 https://github.com/biobakery/maaslin2_benchmark. The following R packages were used to
953 generate the manuscript figures: ComplexHeatmap⁶¹, ggalluvial⁶², ggplot2⁶³, UpSetR⁶⁴, and
954 cowplot⁶⁵.

955 956 **Acknowledgements**

957
958 This work was funded in part by US National Institutes of Health grants U19AI110820 (to Owen
959 White), R01HG005220 (to Rafael Irizarry), and R24DK110499 and U54DK102557 (CH).

961 **Supplementary Materials**

962 **Supplementary Figure S1: Details of simulation parameters, evaluation metrics, and**
963 **benchmarking methods. A.** Four broad metadata designs commonly encountered in
964 microbiome epidemiology for varying sample size, effect size, and feature dimensions are
965 considered: UVA (Single continuous metadata), UVB (Single binary metadata), MVA (Multiple

966 independent metadata), and MVB (Multiple correlated metadata). For each of this broad metadata
967 design, both cross-sectional and longitudinal cases are evaluated (**Methods**). **B.** Three aspects
968 of performance are considered: (i) false discovery, (ii) sensitivity, and (iii) scope and
969 computational efficiency of the associated software, each comprising multiple evaluation metrics
970 (**Methods**). **C.** A combination of statistical models, normalization, and transformation schemes
971 are employed to the synthetic datasets for a variety of association methods, leading up to 84
972 combinations of normalization/transformation, zero-inflation, and regression models.

973

974 **Supplementary Figure S2: Full summary of detection performance for varying effect size,**
975 **sample size, and feature dimensions in the simple case of univariate binary metadata**
976 **without repeated measures.** Both sensitivity and false discovery rates (FDR) are shown for the
977 best-performing methods from each class of methods (as measured by average F1 score). Values
978 are averages over 100 iterations for each parameter combination. The x-axis (effect size) within
979 each panel represents the linear effect size parameter; a higher effect size represents a stronger
980 association. For visualization purposes, the best-performing methods from each class of models
981 (as measured by average F1 score) are shown. Red line parallel to the x-axis is the target
982 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
983 across all simulation parameters in this setting. All methods were parallelized using custom bash
984 scripts in a high-performance computing environment and methods unable to process specific
985 simulation configurations due to high computational overhead or slow convergence were omitted
986 for those cases.

987

988 **Supplementary Figures S3: Meta-summary of detection performance in the simple case of**
989 **univariate binary metadata without repeated measures.** Detection performance measures
990 (Sensitivity, FPR, FDR) for all methods are provided. Values are averages over all parameter
991 combinations each summarized over 100 iterations. Red line parallel to the x-axis is the target

992 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
993 across all simulation parameters in this setting.

994

995 **Supplementary Figures S4: Meta-summary of p-value calibration performance in the**
996 **simple case of univariate binary metadata without repeated measures.** P-value calibration
997 measures as measured by 'departure from uniformity' (Liberal Area, Conservative Area, Total
998 Area) for all methods are provided. Values are averages over all parameter combinations. Values
999 are averages over all parameter combinations each summarized over 100 iterations. Redd line
1000 parallel to the x-axis is the target threshold for FDR in multiple testing. Methods are sorted by
1001 increasing order of average F1 score across all simulation parameters in this setting.

1002

1003 **Supplementary Figure S5: Full summary of detection performance for varying effect size,**
1004 **sample size, and feature dimensions in the simple case of univariate continuous metadata**
1005 **without repeated measures.** Both sensitivity and false discovery rates (FDR) are shown for the
1006 best-performing methods from each class of methods (as measured by average F1 score). Values
1007 are averages over 100 iterations for each parameter combination. The x-axis (effect size) within
1008 each panel represents the linear effect size parameter; a higher effect size represents a stronger
1009 association. For visualization purposes, the best-performing methods from each class of models
1010 (as measured by average F1 score) are shown. Red line parallel to the x-axis is the target
1011 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
1012 across all simulation parameters in this setting. All methods were parallelized using custom bash
1013 scripts in a high-performance computing environment and methods unable to process specific
1014 simulation configurations due to high computational overhead or slow convergence were omitted
1015 for those cases.

1016

1017 **Supplementary Figures S6: Meta-summary of detection performance in the presence of**
1018 **multiple independent covariates without repeated measures.** Detection performance
1019 measures (F1 score, Matthew's correlation coefficient, FDR) for all methods are provided. Values
1020 are averages over all parameter combinations each summarized over 100 iterations. Red line
1021 parallel to the x-axis is the target threshold for FDR in multiple testing. Methods are sorted by
1022 increasing order of average F1 score across all simulation parameters in this setting.

1023

1024 **Supplementary Figure S7: Full summary of detection performance for varying effect size,**
1025 **sample size, and feature dimensions in the presence of multiple independent covariates**
1026 **without repeated measures.** Both sensitivity and false discovery rates (FDR) are shown for the
1027 best-performing methods from each class of methods (as measured by average F1 score). Values
1028 are averages over 100 iterations for each parameter combination. The x-axis (effect size) within
1029 each panel represents the linear effect size parameter; a higher effect size represents a stronger
1030 association. For visualization purposes, the best-performing methods from each class of models
1031 (as measured by average F1 score) are shown. Red line parallel to the x-axis is the target
1032 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
1033 across all simulation parameters in this setting. All methods were parallelized using custom bash
1034 scripts in a high-performance computing environment and methods unable to process specific
1035 simulation configurations due to high computational overhead or slow convergence were omitted
1036 for those cases.

1037

1038 **Supplementary Figures S8: Meta-summary of detection performance in the presence of**
1039 **repeated measures and univariate binary metadata.** Detection performance measures
1040 (Sensitivity, FPR, FDR) for all methods are provided. Values are averages over all parameter
1041 combinations each summarized over 100 iterations. Red line parallel to the x-axis is the target

1042 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
1043 across all simulation parameters in this setting.

1044

1045 **Supplementary Figures S9: Meta-summary of detection performance in the presence of**
1046 **repeated measures and multiple independent covariates.** Detection performance measures
1047 (Sensitivity, FPR, FDR) for all methods are provided. Values are averages over all parameter
1048 combinations each summarized over 100 iterations. Red line parallel to the x-axis is the target
1049 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
1050 across all simulation parameters in this setting.

1051

1052 **Supplementary Figures S10: Meta-summary of detection performance in the presence of**
1053 **repeated measures and univariate continuous metadata.** Detection performance measures
1054 (Sensitivity, FPR, FDR) for all methods are provided. Values are averages over all parameter
1055 combinations each summarized over 100 iterations. Red line parallel to the x-axis is the target
1056 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
1057 across all simulation parameters in this setting.

1058

1059 **Supplementary Figures S11: Meta-summary of detection performance in the presence of**
1060 **repeated measures and multiple correlated covariates.** Detection performance measures
1061 (Sensitivity, FPR, FDR) for all methods are provided. Values are averages over all parameter
1062 combinations each summarized over 100 iterations. Red line parallel to the x-axis is the target
1063 threshold for FDR in multiple testing. Methods are sorted by increasing order of average F1 score
1064 across all simulation parameters in this setting.

1065

1066 **Supplementary Figure S12. Runtime of association methods.** CPU time (in minutes) is shown
1067 for all models faceted by feature dimension (100, 200, 500) and colored by metadata design (i.e.

1068 univariate and multivariable) in both cross-sectional (top) and longitudinal (bottom) settings.
1069 Values are averages over 100 iterations for each parameter combination. All methods were
1070 parallelized using custom bash scripts in a high-performance computing environment and
1071 methods unable to process specific simulation configurations due to high computational overhead
1072 or slow convergence were omitted for those cases.

1073

1074 **Supplementary Figure S13. Performance of multivariable association methods on negative**
1075 **training data across a range of significance levels.** MaAsLin 2's default linear model produced
1076 a consistently lower proportion of significant associations in negative training data (or repeatedly
1077 shuffled training set) (averaged over 1,000 permutations) than the positive training (unshuffled)
1078 counterpart in both baseline and longitudinal models (**Methods**).

1079

1080 **Supplementary Figure S14: Statistically significant overlap of detected features by**
1081 **MaAsLin 2 and those found in the original study.** Contingency tables describing the
1082 intersection of detected features between MaAsLin 2 and Lloyd-Price et al.³⁶ for various data
1083 modalities in the IBDMDB dataset are shown.

1084

1085 **Supplementary Figure S15: Overlap of detected taxonomic features by various MaAsLin**
1086 **models.** Upset plot describing the intersection of detected taxonomic features between various
1087 MaAsLin 2 models in the IBDMDB dataset reveal significant overlap across methods. A similar
1088 pattern was observed for functional profiles.

1089

1090 **Supplementary Datasets S1-S6: MaAsLin 2 associations between HMP2 multi-omics**
1091 **features and covariates.** List of statistically significant associations (FDR<0.25) between IBD
1092 disease phenotype (with non-IBD as reference), IBD dysbiosis state (with non-dysbiotic as
1093 reference), age, and antibiotic use with multiple data modalities (**S1**: species, **S2**: unstratified DNA

1094 pathways, **S3**: unstratified RNA pathways, **S4**: pathway RNA/DNA ratios, **S5**: stratified DNA
1095 pathways, **S6**: stratified RNA pathways) using a multivariable linear mixed effects model
1096 (**Methods**). Features are sorted by minimum FDR-adjusted p-values. For each feature, coefficient
1097 estimates and test statistics and the associated two-tailed p-values are also reported. For each
1098 data modality, input features and metadata are also provided.

1099

1100 **References**

1101


- 1102 1 Lynch, S. V. & Pedersen, O. The Human Intestinal Microbiome in Health and Disease. *N*
1103 *Engl J Med* **375**, 2369-2379, doi:10.1056/NEJMra1600266 (2016).
- 1104 2 Shreiner, A. B., Kao, J. Y. & Young, V. B. The gut microbiome in health and in disease.
1105 *Curr Opin Gastroenterol* **31**, 69-75, doi:10.1097/mog.000000000000139 (2015).
- 1106 3 Franzosa, E. A. *et al.* Sequencing and beyond: integrating molecular 'omics' for microbial
1107 community profiling. *Nat Rev Microbiol* **13**, 360-372, doi:10.1038/nrmicro3451 (2015).
- 1108 4 Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. *Genome Biol* **18**, 83,
1109 doi:10.1186/s13059-017-1215-1 (2017).
- 1110 5 Lloyd-Price, J. *et al.* Strains, functions and dynamics in the expanded Human Microbiome
1111 Project. *Nature* **550**, 61-66, doi:10.1038/nature23889 (2017).
- 1112 6 iHMP Consortium. The Integrative Human Microbiome Project. *Nature* **569**, 641-648,
1113 doi:10.1038/s41586-019-1238-8 (2019).
- 1114 7 Hawinkel, S., Mattiello, F., Bijmans, L. & Thas, O. A broken promise: microbiome
1115 differential abundance methods do not control the false discovery rate. *Brief Bioinform* **20**,
1116 210-221, doi:10.1093/bib/bbx104 (2019).
- 1117 8 Weiss, S. *et al.* Normalization and microbial differential abundance strategies depend
1118 upon data characteristics. *Microbiome* **5**, 27, doi:10.1186/s40168-017-0237-y (2017).
- 1119 9 Thorsen, J. *et al.* Large-scale benchmarking reveals false discoveries and count
1120 transformation sensitivity in 16S rRNA gene amplicon data analysis methods used in
1121 microbiome studies. *Microbiome* **4**, 62, doi:10.1186/s40168-016-0208-8 (2016).
- 1122 10 McMurdie, P. J. & Holmes, S. Waste not, want not: why rarefying microbiome data is
1123 inadmissible. *PLoS Comput Biol* **10**, e1003531, doi:10.1371/journal.pcbi.1003531 (2014).
- 1124 11 Mallick, H. *et al.* Experimental design and quantitative analysis of microbial community
1125 multiomics. *Genome Biol* **18**, 228, doi:10.1186/s13059-017-1359-z (2017).
- 1126 12 Jonsson, V., Österlund, T., Nerman, O. & Kristiansson, E. Statistical evaluation of methods
1127 for identification of differentially abundant genes in comparative metagenomics. *BMC*
1128 *Genomics* **17**, 78, doi:10.1186/s12864-016-2386-y (2016).
- 1129 13 Jonsson, V., Österlund, T., Nerman, O. & Kristiansson, E. Variability in Metagenomic
1130 Count Data and Its Influence on the Identification of Differentially Abundant Genes. *J*
1131 *Comput Biol* **24**, 311-326, doi:10.1089/cmb.2016.0180 (2017).
- 1132 14 Mandal, S. *et al.* Analysis of composition of microbiomes: a novel method for studying
1133 microbial composition. *Microb Ecol Health Dis* **26**, 27663, doi:10.3402/mehd.v26.27663
1134 (2015).
- 1135 15 Morgan, X. C. *et al.* Dysfunction of the intestinal microbiome in inflammatory bowel
1136 disease and treatment. *Genome Biol* **13**, R79, doi:10.1186/gb-2012-13-9-r79 (2012).

- 1137 16 Morgan, X. C. *et al.* Associations between host gene expression, the mucosal microbiome,
1138 and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease.
1139 *Genome Biol* **16**, 67, doi:10.1186/s13059-015-0637-x (2015).
- 1140 17 Zhang, X. *et al.* Negative binomial mixed models for analyzing microbiome count data.
1141 *BMC Bioinformatics* **18**, 4, doi:10.1186/s12859-016-1441-7 (2017).
- 1142 18 Sharpton, T. *et al.* Development of Inflammatory Bowel Disease Is Linked to a Longitudinal
1143 Restructuring of the Gut Metagenome in Mice. *mSystems* **2**,
1144 doi:10.1128/mSystems.00036-17 (2017).
- 1145 19 Armour, C. R., Nayfach, S., Pollard, K. S. & Sharpton, T. J. A Metagenomic Meta-analysis
1146 Reveals Functional Signatures of Health and Disease in the Human Gut Microbiome.
1147 *mSystems* **4**, doi:10.1128/mSystems.00332-18 (2019).
- 1148 20 Xinyan, Z., Himel, M. & Nengjun, Y. Zero-inflated negative binomial regression for
1149 differential abundance testing in microbiome studies. *Journal of Bioinformatics and*
1150 *Genomics*, 1-1 (2016).
- 1151 21 Paulson, J. N., Stine, O. C., Bravo, H. C. & Pop, M. Differential abundance analysis for
1152 microbial marker-gene surveys. *Nat Methods* **10**, 1200-1202, doi:10.1038/nmeth.2658
1153 (2013).
- 1154 22 Kaul, A., Mandal, S., Davidov, O. & Peddada, S. D. Analysis of Microbiome Data in the
1155 Presence of Excess Zeros. *Front Microbiol* **8**, 2114, doi:10.3389/fmicb.2017.02114
1156 (2017).
- 1157 23 Peng, X., Li, G. & Liu, Z. Zero-Inflated Beta Regression for Differential Abundance
1158 Analysis with Metagenomics Data. *J Comput Biol* **23**, 102-110,
1159 doi:10.1089/cmb.2015.0157 (2016).
- 1160 24 Chen, E. Z. & Li, H. A two-part mixed-effects model for analyzing longitudinal microbiome
1161 compositional data. *Bioinformatics* **32**, 2611-2617, doi:10.1093/bioinformatics/btw308
1162 (2016).
- 1163 25 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
1164 for RNA-seq data with DESeq2. *Genome Biol* **15**, 550, doi:10.1186/s13059-014-0550-8
1165 (2014).
- 1166 26 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
1167 differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-
1168 140, doi:10.1093/bioinformatics/btp616 (2010).
- 1169 27 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing
1170 and microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).
- 1171 28 Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model
1172 analysis tools for RNA-seq read counts. *Genome Biol* **15**, R29, doi:10.1186/gb-2014-15-
1173 2-r29 (2014).
- 1174 29 Smyth, G. K. Linear models and empirical bayes methods for assessing differential
1175 expression in microarray experiments. *Stat Appl Genet Mol Biol* **3**, Article3,
1176 doi:10.2202/1544-6115.1027 (2004).
- 1177 30 Van den Berge, K. *et al.* Observation weights unlock bulk RNA-seq tools for zero inflation
1178 and single-cell applications. *Genome Biol* **19**, 24, doi:10.1186/s13059-018-1406-4 (2018).
- 1179 31 McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis
1180 and graphics of microbiome census data. *PLoS One* **8**, e61217,
1181 doi:10.1371/journal.pone.0061217 (2013).
- 1182 32 Calgaro, M., Romualdi, C., Waldron, L., Risso, D. & Vitulo, N. Assessment of statistical
1183 methods from single cell, bulk RNA-seq, and metagenomics applied to microbiome data.
1184 *Genome Biol* **21**, 191, doi:10.1186/s13059-020-02104-1 (2020).
- 1185 33 Anders, S. & Huber, W. Differential expression analysis for sequence count data. *Genome*
1186 *Biol* **11**, R106, doi:10.1186/gb-2010-11-10-r106 (2010).


- 1187 34 Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression
1188 analysis of RNA-seq data. *Genome Biol* **11**, R25, doi:10.1186/gb-2010-11-3-r25 (2010).
- 1189 35 McKnight, D. T. *et al.* Methods for normalizing microbiome data: an ecological perspective.
1190 *Methods in Ecology and Evolution* **10**, 389-400 (2019).
- 1191 36 Lloyd-Price, J. *et al.* Multi-omics of the gut microbial ecosystem in inflammatory bowel
1192 diseases. *Nature* **569**, 655-662, doi:10.1038/s41586-019-1237-9 (2019).
- 1193 37 Franzosa, E. A. *et al.* Species-level functional profiling of metagenomes and
1194 metatranscriptomes. *Nat Methods* **15**, 962-968, doi:10.1038/s41592-018-0176-y (2018).
- 1195 38 Caspi, R. *et al.* The MetaCyc database of metabolic pathways and enzymes. *Nucleic Acids*
1196 *Res* **46**, D633-d639, doi:10.1093/nar/gkx935 (2018).
- 1197 39 Truong, D. T. *et al.* MetaPhlan2 for enhanced metagenomic taxonomic profiling. *Nat*
1198 *Methods* **12**, 902-903, doi:10.1038/nmeth.3589 (2015).
- 1199 40 Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful
1200 approach to multiple testing. *Journal of the Royal statistical society: series B*
1201 *(Methodological)* **57**, 289-300 (1995).
- 1202 41 Schirmer, M. *et al.* Dynamics of metatranscription in the inflammatory bowel disease gut
1203 microbiome. *Nat Microbiol* **3**, 337-346, doi:10.1038/s41564-017-0089-z (2018).
- 1204 42 Hawinkel, S., Rayner, J. C. W., Bijmans, L. & Thas, O. Sequence count data are poorly fit
1205 by the negative binomial distribution. *PLoS One* **15**, e0224909,
1206 doi:10.1371/journal.pone.0224909 (2020).
- 1207 43 Venables, W. N. & Ripley, B. D. *Modern applied statistics with S-PLUS*. (Springer Science
1208 & Business Media, 2013).
- 1209 44 Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects models
1210 using lme4. *Journal of Statistical Software* **67** (2015).
- 1211 45 Zeileis, A., Kleiber, C. & Jackman, S. Regression models for count data in R. *Journal of*
1212 *statistical software* **27**, 1-25 (2008).
- 1213 46 Aitchison, J. The statistical analysis of compositional data. *Journal of the Royal Statistical*
1214 *Society: Series B (Methodological)* **44**, 139-160 (1982).
- 1215 47 Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V. & Egozcue, J. J. Microbiome Datasets
1216 Are Compositional: And This Is Not Optional. *Front Microbiol* **8**, 2224,
1217 doi:10.3389/fmicb.2017.02224 (2017).
- 1218 48 VanderWeele, T. J. Mediation Analysis: A Practitioner's Guide. *Annu Rev Public Health*
1219 **37**, 17-32, doi:10.1146/annurev-publhealth-032315-021402 (2016).
- 1220 49 Ma, S. *et al.* Population Structure Discovery in Meta-Analyzed Microbial Communities and
1221 Inflammatory Bowel Disease. *bioRxiv* (2020).
- 1222 50 Gibson, T. E. & Gerber, G. K. Robust and scalable models of microbiome dynamics. *arXiv*
1223 *preprint arXiv:1805.04591* (2018).
- 1224 51 Ren, B. S., E, Tickle, T; Huttenhower, C sparseDOSSA: Sparse Data Observations for
1225 Simulating Synthetic Abundance. R package version 1.12.0. (2020).
- 1226 52 Gevers, D. *et al.* The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host*
1227 *Microbe* **15**, 382-392, doi:10.1016/j.chom.2014.02.005 (2014).
- 1228 53 Imhann, F. *et al.* Interplay of host genetics and gut microbiota underlying the onset and
1229 clinical presentation of inflammatory bowel disease. *Gut* **67**, 108-119, doi:10.1136/gutjnl-
1230 2016-312135 (2018).
- 1231 54 Cui, S., Ji, T., Li, J., Cheng, J. & Qiu, J. What if we ignore the random effects when
1232 analyzing RNA-seq data in a multifactor experiment. *Stat Appl Genet Mol Biol* **15**, 87-105,
1233 doi:10.1515/sagmb-2015-0011 (2016).
- 1234 55 Stasinopoulos, D. M. & Rigby, R. A. Generalized additive models for location scale and
1235 shape (GAMLSS) in R. (2007).
- 1236 56 Zhang, Y. Likelihood-based and bayesian methods for tweedie compound poisson linear
1237 mixed models. *Statistics and Computing* **23**, 743-757 (2013).

- 1238 57 Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. ROCR: visualizing classifier
1239 performance in R. *Bioinformatics* **21**, 3940-3941, doi:10.1093/bioinformatics/bti623
1240 (2005).
- 1241 58 Sonesson, C. & Robinson, M. D. Bias, robustness and scalability in single-cell differential
1242 expression analysis. *Nat Methods* **15**, 255-261, doi:10.1038/nmeth.4612 (2018).
- 1243 59 Caspi, R. *et al.* The MetaCyc database of metabolic pathways and enzymes and the
1244 BioCyc collection of Pathway/Genome Databases. *Nucleic Acids Res* **42**, D459-471,
1245 doi:10.1093/nar/gkt1103 (2014).
- 1246 60 McIver, L. J. *et al.* bioBakery: a meta'omic analysis environment. *Bioinformatics* **34**, 1235-
1247 1237, doi:10.1093/bioinformatics/btx754 (2018).
- 1248 61 Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in
1249 multidimensional genomic data. *Bioinformatics* **32**, 2847-2849,
1250 doi:10.1093/bioinformatics/btw313 (2016).
- 1251 62 Brunson, J. C. ggalluvial: Layered Grammar for Alluvial Plots. *Journal of Open Source*
1252 *Software* **5**, 2017 (2020).
- 1253 63 Wickham, H. *ggplot2: elegant graphics for data analysis*. (springer, 2016).
- 1254 64 Lex, A., Gehlenborg, N., Strobel, H., Vuillemot, R. & Pfister, H. UpSet: visualization of
1255 intersecting sets. *IEEE transactions on visualization and computer graphics* **20**, 1983-
1256 1992 (2014).
- 1257 65 Wilke, C. O., Wickham, H. & Wilke, M. C. O. Package 'cowplot'. *Streamlined Plot Theme*
1258 *and Plot Annotations for 'ggplot2* (2019).
- 1259

A. MaAsLin 2 - A framework for microbiome epidemiology



C. Large-scale evaluation of multivariable association methods



B. Comprehensive benchmarking using synthetic abundances




Figure 1

Differential abundance detection performance

Single binary metadata without repeated measures




Figure 2

Multivariable association detection performance

Multiple covariates without repeated measures




Figure 3







Figure 4




Figure 5